Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Oral Platinum Agent Satraplatin (JM-216) in Combination With Docetaxel in Treatment of Advanced Malignancies

NCT00125411 is registered in ClinicalTrials.gov with Agennix as lead sponsor.

NCT NCT00125411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00125411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Oral Platinum Agent Satraplatin (JM-216) in Combination With Docetaxel in Treatment of Advanced Malignancies
Lead sponsor
Agennix
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2007
Completion date
February 28, 2009
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tumors